HYJURNY
Dead / Abandoned — Abandoned — no statement of use filed (as of 05 Oct 2026)
What this means for you
This application is over — abandoned 05 Oct 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97566239
- Mark type
- Word mark
- Filed
- 26 Aug 2022
- Published for opposition
- 11 Jul 2023
- Abandoned
- 05 Oct 2026
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, New York, NY, US
Prosecution history
- 05 Oct 2026 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 05 Oct 2026 — ABANDONMENT - NO USE STATEMENT FILED
- 24 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Jun 2026 — SOU EXTENSION 5 GRANTED
- 11 Feb 2026 — SOU EXTENSION 5 FILED
- 23 Jun 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 12 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 27 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Aug 2025 — SOU EXTENSION 4 GRANTED
- 26 Aug 2025 — SOU EXTENSION 4 FILED
- 26 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 05 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Mar 2025 — SOU EXTENSION 3 GRANTED
- 04 Mar 2025 — SOU EXTENSION 3 FILED
- 04 Mar 2025 — SOU TEAS EXTENSION RECEIVED